The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer

导出原文传递

翻译打印收藏纠错

作者： Saad, Fred ^[1] ; Sternberg, Cora N. ^[2] ; Mulders, Peter F. A. ^[3] ; Niepel, Daniela ^[4] ; Tombal, Bertrand F. ^[5]

作者单位： Amgen Europe GmbH, Zug, Switzerland ^[1] Catholic Univ Louvain, Inst Rech Clin, Serv Urol, Brussels, Belgium ^[2] San Camillo Forlanini Hosp, Dept Med Oncol, Rome, Italy ^[3] Radboud Univ Nijmegen Med Ctr, Nijmegen, Netherlands ^[4] Ctr Hosp Univ Montreal, Div Urol, Montreal, PQ, Canada ^[5]

关键词 Prostate cancer Bisphosphonates Abiraterone acetate Denosumab Zoledronic acid Enzalutamide Radium-223

发布时间 2019-03-16

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览1

Cancer Treatment Reviews

2018年68卷

25-37页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer

Cancer Treatment Reviews

相似文献

Cancer Treatment Reviews

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer

Cancer Treatment Reviews

相似文献

Cancer Treatment Reviews

相关期刊

检索历史清除